Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

815.38 +9.45 (+1.17%)

Streaming Delayed Price Updated: 11:07 AM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

November 20, 2025

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Via Chartmill

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday.

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 20, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss ↗

November 20, 2025

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.

Via Benzinga

Which S&P500 stocks are moving before the opening bell on Thursday? ↗

November 20, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.

Via Chartmill

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout

November 19, 2025

New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released...

Via MarketMinute

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals (NASDAQ:REGN) Screens as a Compelling Value Investment ↗

November 18, 2025

Regeneron (REGN) appears undervalued with a low P/E ratio, strong profitability, and a rock-solid financial health profile. A compelling value stock.

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

November 17, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

1 S&P 500 Stock with Exciting Potential and 2 We Question

November 16, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

What's going on in today's session: S&P500 movers ↗

November 13, 2025

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Via Chartmill

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Wall Street Falls On US Government Reopening Day, Bitcoin Slides To $100,000: What's Moving Markets Thursday? ↗

November 13, 2025

Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S. history, as investors aggressively repriced Fed rate-cut expectations...

Via Benzinga

Topics Economy

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

November 13, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗

November 13, 2025

These top growth stocks have plenty of room left to run.

Via The Motley Fool

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

Via Benzinga

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack

November 10, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with...

Via StockStory

Topics Artificial Intelligence

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

November 10, 2025

Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.

Via Investor's Business Daily

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

November 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

November 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

November 06, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗

November 04, 2025

Via Benzinga

The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality

November 04, 2025

In the dynamic world of finance, where fortunes are made and lost in the blink of an eye, a chilling sentiment has begun to grip investors: the idea that stocks can, indeed, go down. This isn't merely...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

November 04, 2025

Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit...

Via StockStory

Topics Earnings

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗

November 03, 2025

Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.